Illustration of time at risk of IMD, MCV4 vaccination uptake and

Download scientific diagram | Illustration of time at risk of IMD, MCV4 vaccination uptake and duration of protection from MCV4 in all cohorts studied. IMD = Invasive meningococcal disease, MCV4 = meningococcal ACWY conjugate vaccine from publication: Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine | In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended | Meningococcal Vaccines, Conjugate Vaccines and Vaccines | ResearchGate, the professional network for scientists.

Frontiers Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco

Full article: Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada

Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. - Abstract - Europe PMC

WO2016132294A1 - Neisseria meningitidis compositions and methods thereof - Google Patents

Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs, BMC Public Health

Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada

PDF) Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment

Quadrivalent Meningococcal Vaccine Uptake Among Men Who Have Sex With Men During a Meningococcal Outbreak in Los Angeles County, California, 2016-2017 - Ian W. Holloway, Elizabeth S. C. Wu, Jennifer Gildner, Vincent